Dover has entered right into a definitive settlement to amass Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and management instruments for the biopharmaceutical, semiconductor and industrial sectors.
เพรสเชอร์เกจnuovafima will broaden Dover’s biopharma single-use production offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate approximately US$40 million–45 million in revenue through the full yr 2022.
When the deal closes, Malema will turn into part of the PSG business unit within Dover’s Pumps & Process Solutions segment.
“We see an amazing long-term development alternative within the bioprocessing trade pushed by a strong and growing pipeline of effective novel biologic medicine, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of extra environment friendly single-use production processes helps a strong outlook for our offerings of single-use components to end-customers. We imagine that pairing Malema’s know-how with our present portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and value proposition of our options to our prospects.”
“We are methodically building out our biopharma platform by way of proactive capability additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest part applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing know-how and further strengthens our sensor portfolio with new proprietary technology. In addition to engaging biopharma functions, we expect sturdy development in the semiconductor area on the capability expansion and re-shoring tailwinds.”
Share